|Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer|
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
|Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors|
LV Sequist, BA Waltman, D Dias-Santagata, S Digumarthy, AB Turke, ...
Science translational medicine 3 (75), 75ra26-75ra26, 2011
|Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK|
AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ...
Journal of clinical oncology 27 (26), 4247, 2009
|ROS1 rearrangements define a unique molecular class of lung cancers|
K Bergethon, AT Shaw, SHI Ou, R Katayama, CM Lovly, NT McDonald, ...
Journal of clinical oncology 30 (8), 863, 2012
|Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases|
JN Vauthey, TM Pawlik, D Ribero, TT Wu, D Zorzi, PM Hoff, HQ Xiong, ...
Journal of Clinical Oncology 24 (13), 2065-2072, 2006
|International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology|
T Shimosegawa, ST Chari, L Frulloni, T Kamisawa, S Kawa, ...
Pancreas 40 (3), 352-358, 2011
|Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers|
R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ...
Science translational medicine 4 (120), 120ra17-120ra17, 2012
|Functional genomics reveal that the serine synthesis pathway is essential in breast cancer|
R Possemato, KM Marks, YD Shaul, ME Pacold, D Kim, K Birsoy, ...
Nature 476 (7360), 346, 2011
|Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population|
SJ Rodig, M Mino-Kenudson, S Dacic, BY Yeap, A Shaw, JA Barletta, ...
Clinical cancer research 15 (16), 5216-5223, 2009
|EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib|
RB Corcoran, H Ebi, AB Turke, EM Coffee, M Nishino, AP Cogdill, ...
Cancer discovery 2 (3), 227-235, 2012
|EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer (NSCLC): a retrospective analysis|
JF Gainor, AT Shaw, LV Sequist, X Fu, CG Azzoli, Z Piotrowska, ...
Clinical cancer research, clincanres. 3101.2015, 2016
|Molecular mechanisms of resistance to first-and second-generation ALK inhibitors in ALK-rearranged lung cancer|
JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ...
Cancer discovery 6 (10), 1118-1133, 2016
|Patient-derived models of acquired resistance can identify effective drug combinations for cancer|
AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ...
Science 346 (6216), 1480-1486, 2014
|Sensitive sequencing method for KRAS mutation detection by Pyrosequencing|
S Ogino, T Kawasaki, M Brahmandam, L Yan, M Cantor, C Namgyal, ...
The Journal of molecular diagnostics 7 (3), 413-421, 2005
|mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake|
ÖH Yilmaz, P Katajisto, DW Lamming, Y Gültekin, KE Bauer-Rowe, ...
Nature 486 (7404), 490, 2012
|A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry|
M Mino-Kenudson, LR Chirieac, K Law, JL Hornick, N Lindeman, EJ Mark, ...
Clinical Cancer Research 16 (5), 1561-1571, 2010
|Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal …|
CG Willett, Y Boucher, DG Duda, E di Tomaso, LL Munn, RT Tong, ...
Journal of clinical oncology: official journal of the American Society of …, 2005
|Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection|
JR Rodriguez, R Salvia, S Crippa, AL Warshaw, C Bassi, M Falconi, ...
Gastroenterology 133 (1), 72-79, 2007
|Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients|
S Crippa, R Salvia, AL Warshaw, I Domínguez, C Bassi, M Falconi, ...
Annals of surgery 247 (4), 571, 2008
|Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy|
C Pfirschke, C Engblom, S Rickelt, V Cortez-Retamozo, C Garris, F Pucci, ...
Immunity 44 (2), 343-354, 2016